All News
Filter News
Found 877 articles
-
Gilead Sciences Announces Updated 2020 Guidance
1/11/2021
Gilead Sciences, Inc. announced the company has revised certain elements of its full year 2020 guidance.
-
Selvita completes acquisition of Fidelta from Galapagos
1/4/2021
Galapagos NV and Selvita S.A. announced that the strategic transaction in which Selvita has acquired Fidelta from Galapagos has been completed.
-
A little more than one year after Gilead Sciences and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies have pulled the plug on that goal.
-
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)
12/15/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib).
-
Preclinical contract research organization (CRO) Selvita has entered into a deal with Galapagos to acquire its inflammation-, fibrosis- and anti-infectives-focused CRO Fidelta.
-
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis
11/2/2020
Gilead Sciences, Inc. and Galapagos NV announced that the application for a new indication to the approved license for filgotinib 200 mg, an oral JAK1 preferential inhibitor, has been validated and is now under evaluation by the European Medicines Agency.
-
Gilead Sciences Announces Third Quarter 2020 Financial Results
10/28/2020
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2020.
-
Clinical Catch-Up: October 12-16
10/19/2020
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look. -
Back to the Drawing Board: Galapagos and Servier's Arthritis Knee Repair Drug Fails Phase II
10/16/2020
Galapagos NV and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet its primary endpoint in osteoarthritis knee repair. -
Phase 2b/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis
10/12/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis (UC).
-
18th U.S. Surgeon General Joins Scipher Medicine
10/8/2020
Scipher Medicine, a precision immunology company matching patients with most effective therapy, has appointed former United States Surgeon General Regina Benjamin, MD, MBA, to its Board of Advisors.
-
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
9/25/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral,
-
Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis
9/25/2020
Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials
-
Ryvu Therapeutics Reports 2020 Half-Year Financial Results
9/15/2020
Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, reported today its 2020 H1 financial results and provided a corporate update. " At Ryvu, we always excelled in moving forward at a rapid pace; however, the first half
-
The company indicates the agency requested data from the MANTA and MANTA-Ray trials before completing its review of filgotinib. Here's more about it.
-
Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
8/18/2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA).
-
Gilead Sciences Announces Second Quarter and First Half 2020 Financial Results
7/30/2020
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter and first half 2020.
-
Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis
7/24/2020
Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca ® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis -- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- FOSTER CITY, Calif., & MECHELEN, Belgium--( BUSINESS WIRE )-- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronex
-
Forbion Announces First Close of Forbion Growth Opportunities Fund at EUR 185 Million (USD 208 Million)
7/9/2020
Forbion, a leading European life sciences venture capital firm, announces the first close at EUR 185 million of its new Forbion Growth Opportunities Fund, focused on investing in late-stage European life sciences companies.
-
Open Source Imaging Consortium (OSIC) Launches $55,000 AI Competition to Help Pulmonary Fibrosis Patients
7/7/2020
The OSIC Pulmonary Fibrosis Progression Will Challenge the World's Brightest Data Science Minds to Predict Lung Function Decline by Using Machine Learning